Abstract 896P
Background
This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs).
Methods
In this prospective, single-arm, single-centre clinical trial, patients meeting the inclusion criteria were treated neoadjuvant therapy of preoperatively with 200 mg pembrolizumab combined with 75 mg/m2 cisplatin and 175 mg/m2 paclitaxel. This was followed by surgery and postoperative adjuvant therapy. The primary endpoint was the postoperative pathological complete response (PCR) rate. All statistical analyses were performed using SPSS 26.
Results
A total of 22 patients were enrolled, and the baseline characteristics were shown in Fig. 1. The postoperative PCR rate, was 36.4% (8/22), and there was no delay to surgery due to adverse drug reactions. The rate of laryngeal function preservation was 90.9% (20/22). Delayed wound healing was the main surgical complication, with an incidence of 22.7% (5/22). The median follow-up time was 9.5 months, and only 1 patient (4.55%) suffered a regional recurrence.
Table: 896P
Variables | Number of patients | % |
Male/Female | 21/1 | |
Age (mean ± SD, years) | 58.1±10.49 (22∼69) | -- |
Primary site | ||
Oropharynx | 6 | 27.3 |
hypopharynx | 15 | 68.2 |
Oral Cavity | 1 | 4.5 |
Hypopharynx invasion (N=15) | ||
Fixed vocal cord | 9 | 60 |
Extend to esophagus | 2 | 13.3 |
Tobacco | ||
YES | 16 | 72.7 |
NO | 6 | 27.3 |
Alcohol | ||
YES | 15 | 68.2 |
NO | 7 | 31.8 |
P16 states | ||
Positive | 4 | 18.2 |
Negative | 18 | 81.8 |
T stage | ||
T1-T2 | 8 | 36.4 |
T3 | 7 | 31.8 |
T4 | 7 | 31.8 |
N stage | ||
N0-N1 | 3 | 13.6 |
N2 | 19 | 86.4 |
Stage | ||
II | 3 | 13.6 |
III | 3 | 13.6 |
IV | 16 | 72.7 |
PD-L1 combined positive score | ||
<5 | 7 | 31.8 |
5-10 | 2 | 9.1 |
≥10 | 13 | 59.1 |
Conclusions
Preoperative treatment with pembrolizumab and chemotherapy in resectable LA-HNSCC has a high PCR rate with no significant impact on surgical safety. This treatment was found to increase the rate of laryngeal function preservation. However, the effects of neoadjuvant immunotherapy on long-term prognosis in LA-HNSCCs require further study.
Clinical trial identification
Trial registration: Chinese Clinical Trial Registry, ChiCTR2200055719, Registered 16 January 2022.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hope Run Special Fund of Cancer Foundation of China (Grant No.LC2021A16).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
818TiP - REFRaME-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha (FolRα)
Presenter: R. Wendel Naumann
Session: Poster session 12
819TiP - FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours
Presenter: Funda Meric-Bernstam
Session: Poster session 12
820TiP - A randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P trial)
Presenter: Hyun-woong Cho
Session: Poster session 12
821TiP - Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
Presenter: Geoffrey Shapiro
Session: Poster session 12
862P - Clinical utility of circulating tumor HPV16 DNA detection in plasma from oropharyngeal squamous cell carcinoma patients
Presenter: Ana Carolina de Carvalho
Session: Poster session 12
863P - Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
Presenter: Danilo Galizia
Session: Poster session 12
864P - Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery
Presenter: Grégoire Marret
Session: Poster session 12
865P - Molecular analysis of surgical margins in early oral carcinomas (OSCC)
Presenter: Antoine Moya-Plana
Session: Poster session 12
866P - Prognostic performance of a genome-wide methylome enrichment platform in head and neck cancer
Presenter: Geoffrey Liu
Session: Poster session 12
867P - Predicting HPV-association using regular H&E slides can identify subgroups of patients with favorable prognosis at a highly detailed level
Presenter: Jens Peter Klussmann
Session: Poster session 12